Skip to main content

Table 4 Relationship between MPC2 expression and clinicopathological features of prostate cancer

From: MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer

Clinicopathologic n MPC2 expression
Variable   Positive Weak positive Negative P value1
  88 23(26.14%) 49(55.68%) 16(18.18)  
Age(yr)      0.652
≤71 45 10(22.22%) 27(60.00%) 8(17.78%)  
>71 43 13(30.23%) 22(51.16%) 8(18.60%)  
Gleason score      0.367
<7 27 9(33.33%) 12(44.44%) 6(22.22%)  
7–10 61 14(22.95%) 37(60.66%) 10(16.39%)  
PSA (ng/ml)      0.763a
≤10 10 4(40.00%) 5(50.00%) 1(10.00%)  
> 10 and ≤ 20 10 1(10.00%) 5(50.00%) 4(40.00%)  
> 20 68 18(26.48%) 39(57.35%) 11(16.18%)  
UICC stage      0.000
pT2 67 13(19.40%) 47(70.15%) 7(10.45%)  
pT3-pT4 21 10(47.62%) 2(9.52%) 9(42.86%)  
lymph node metastasis      0.002
Negative 74 22(29.73%) 43(58.11%) 9(12.16%)  
Positive 14 1(7.14%) 6(42.86%) 7(50.00%)  
distant metastasis      0.939
Negative 63 17(26.98%) 35(55.56%) 11(17.46%)  
Positive 25 6(24.00%) 14(56.00%) 5(20.00%)  
  1. 1Pearson Chi-Square test; a Fisher’s exact probabilities test